Efficacy and Biomarker Results for Pembrolizumab in Soft Tissue and Bone Sarcomas

June 3, 2017
Lisa H. Butterfield, PhD

Lisa H. Butterfield, PhD, discusses efficacy and biomarker results of the phase II SARC028 study, which explored pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas, during the 2017 ASCO Annual Meeting.